Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.27 - [histone H3]-dimethyl-L-lysine36 demethylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.
Lysine demethylase 2 (KDM2B) regulates hippo pathway via MOB1 to promote pancreatic ductal adenocarcinoma (PDAC) progression.
Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Arthritis, Rheumatoid
KDM4B Overexpression Promotes the Growth, Migration, and Invasion of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Activating STAT3 Pathway.
Ataxia Telangiectasia
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Atherosclerosis
Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL.
Bone Diseases, Metabolic
Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.
Brain Diseases
KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels.
Brain Neoplasms
KDM2B Recruitment of the Polycomb Group Complex, PRC1.1, Requires Cooperation between PCGF1 and BCORL1.
Breast Neoplasms
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Clipping of arginine-methylated histone tails by JMJD5 and JMJD7.
Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas.
Comparative analysis of triple-negative breast cancer transcriptomics of Kenyan, African American and Caucasian Women.
Crystal Structure and Functional Analysis of JMJD5 Indicate an Alternate Specificity and Function.
Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro.
Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis.
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia.
KDM4 inhibition targets breast cancer stem-like cells.
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.
Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Lysine demethylase KDM3A regulates nanophotonic hyperthermia resistance generated by 2D silicene in breast cancer.
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation.
Oncogenic features of the JMJD2A histone demethylase in breast cancer.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription.
SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
The Histone Demethylase Enzymes KDM3A and KDM4B Co-Operatively Regulate Chromatin Transactions of the Estrogen Receptor in Breast Cancer.
Burkitt Lymphoma
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Carcinogenesis
CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Crystal Structure and Functional Analysis of JMJD5 Indicate an Alternate Specificity and Function.
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.
GASC1 promotes glioma progression by enhancing NOTCH1 signaling.
Histone demethylase KDM2A: Biological functions and clinical values (Review).
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Identification and functional implication of nuclear localization signals in the N-terminal domain of JMJD5.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
JMJD5 is a potential oncogene for colon carcinogenesis.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
LncRNA LINC01278 accelerates colorectal cancer progression via miR-134-5p/KDM2A axis.
p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis.
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.
Retraction.
Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
The Emerging Role of Lysine Demethylases in DNA Damage Response: Dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites.
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-?2 transcription.
Wnt-Induced Stabilization of KDM4C Is Required for Wnt/?-Catenin Target Gene Expression and Glioblastoma Tumorigenesis.
Carcinoma
A novel amplicon at 9p23 - 24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB.
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Electrophilic Zinc Homoenolates: Synthesis of Cyclopropylamines from Cyclopropanols and Amines.
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Identification and characterization of JMJD2 family genes in silico.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line.
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Carcinoma in Situ
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Carcinoma, Ductal
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Carcinoma, Hepatocellular
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686.
GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells.
RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A.
Carcinoma, Intraductal, Noninfiltrating
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Carcinoma, Non-Small-Cell Lung
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
JMJD2 promotes acquired cisplatin resistance in non-small cell lung carcinoma cells.
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
Carcinoma, Ovarian Epithelial
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Carcinoma, Renal Cell
KDM3A is not associated with metastasis and prognosis of breast cancer.
Carcinoma, Squamous Cell
A novel amplicon at 9p23 - 24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB.
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
Cardiomegaly
The Histone Demethylase JMJD2A Modulates the Induction of Hypertrophy Markers in iPSC-Derived Cardiomyocytes.
The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
Cardiomyopathy, Hypertrophic
The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
Chordoma
365?Epigenetic Profiling Reveals a Unique Histone Code in Chordoma.
Colitis
Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction.
Colonic Neoplasms
A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin.
CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Mutation and expression alterations of histone methylation-related NSD2, KDM2B and SETMAR genes in colon cancers.
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
Colorectal Neoplasms
Activation of TC10-Like Transcription by Lysine Demethylase KDM4B in Colorectal Cancer Cells.
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Histone lysine demethylase 3B (KDM3B) regulates the propagation of autophagy via transcriptional activation of autophagy-related genes.
KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation.
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway.
Dermatitis
Possible Role of Lysine Demethylase 2A in the Pathophysiology of Psoriasis.
Diabetes Mellitus, Type 1
Epigenetic changes related to glucose metabolism in type 1 diabetes after BCG vaccinations: A vital role for KDM2B.
Reduced Histone H3 Lysine 9 Methylation Contributes to the Pathogenesis of Latent Autoimmune Diabetes in Adults via Regulation of SUV39H2 and KDM4C.
Endometrial Neoplasms
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Epstein-Barr Virus Infections
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Esophageal Neoplasms
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Esophageal Squamous Cell Carcinoma
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
GASC1 Promotes Stemness of Esophageal Squamous Cell Carcinoma via NOTCH1 Promoter Demethylation.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Identification and characterization of JMJD2 family genes in silico.
Mitochondrial pathway of the lysine demethylase 5C inhibitor CPI-455 in the Eca-109 esophageal squamous cell carcinoma cell line.
Fibroadenoma
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Gastrointestinal Stromal Tumors
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Glioblastoma
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
MicroRNA?3666 suppresses the growth and migration of glioblastoma cells by targeting KDM2A.
Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
Wnt-Induced Stabilization of KDM4C Is Required for Wnt/?-Catenin Target Gene Expression and Glioblastoma Tumorigenesis.
Glioma
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
GASC1 promotes glioma progression by enhancing NOTCH1 signaling.
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
The histone demethylase JMJD2A promotes glioma cell growth via targeting Akt-mTOR signaling.
Glomerulonephritis
MicroRNA-340-5p inhibits endothelial apoptosis, inflammatory response, and pro-coagulation by targeting KDM4C in anti-neutrophil cytoplasmic antibody (ANCA)-mediated glomerulonephritis through activation of B cells.
Hemangiosarcoma
KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
Hematologic Neoplasms
Changes in IDH2, TET2 and KDM2B Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines.
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Hepatitis B
Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx.
Herpes Simplex
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Herpesviridae Infections
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Hodgkin Disease
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
Hypersensitivity
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Infarction, Middle Cerebral Artery
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Infections
BCL6 corepressor contributes to Th17 cell formation by inhibiting Th17 fate suppressors.
Epigenetic factor siRNA screen during primary KSHV infection identifies novel host restriction factors for the lytic cycle of KSHV.
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
JMJD5 is a potential oncogene for colon carcinogenesis.
KDM2B Overexpression Facilitates Lytic De Novo KSHV Infection by Inducing AP-1 Activity Through Interaction with the SCF E3 Ubiquitin Ligase Complex.
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Insulin Resistance
Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.
Intellectual Disability
A KDM5-Prospero transcriptional axis functions during early neurodevelopment to regulate mushroom body formation.
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Caregiver-reported characteristics of children diagnosed with pathogenic variants in KDM5C.
Heterozygous Variants in KDM4B Lead to Global Developmental Delay and Neuroanatomical Defects.
Mechanisms of Origin, Phenotypic Effects and Diagnostic Implications of Complex Chromosome Rearrangements.
PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an N{varepsilon}-dimethyl lysine demethylase.
Positional cloning and comprehensive mutation analysis identified a novel KDM2B mutation in a Japanese family with minor malformations, intellectual disability, and schizophrenia.
The histone demethylase KDM5 is required for synaptic structure and function at the Drosophila neuromuscular junction.
Ischemic Stroke
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Latent Autoimmune Diabetes in Adults
Reduced Histone H3 Lysine 9 Methylation Contributes to the Pathogenesis of Latent Autoimmune Diabetes in Adults via Regulation of SUV39H2 and KDM4C.
Leukemia
A KDM4A-PAF1-mediated epigenomic network is essential for acute myeloid leukemia cell self-renewal and survival.
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Critical role of Jumonji domain of JMJD1C in MLL-rearranged leukemia.
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
Report of the First Clinical Case of a Moroccan Kabuki Patient with a Novel MLL2 Mutation.
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Leukemia, Myeloid
Changes in IDH2, TET2 and KDM2B Gene Expression After Treatment With Classic Chemotherapeutic Agents and Decitabine in Myelogenous Leukemia Cell Lines.
Leukemia, Myeloid, Acute
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
KDM4C contributes to cytarabine resistance in acute myeloid leukemia via regulating the miR-328-3p/CCND2 axis through MALAT1.
Overexpression of KDM4D promotes acute myeloid leukemia cell development by activating MCL-1.
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
Liver Neoplasms
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Lung Neoplasms
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
CSNK1A1, KDM2A, and LTB4R2 Are New Druggable Vulnerabilities in Lung Cancer.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
KLF8 overexpression promotes the growth of human lung cancer cells by promoting the expression of JMJD2A.
MicroRNA-449a delays lung cancer development through inhibiting KDM3A/HIF-1? axis.
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGF-?2 transcription.
Lymphatic Metastasis
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Lymphoma
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
Lymphoma, B-Cell
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Lymphoma, Large B-Cell, Diffuse
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Macular Degeneration
Histone Demethylase Expression Enhances Human Somatic Cell Nuclear Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells.
Medulloblastoma
Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma.
Melanoma
Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.
Memory Disorders
Increase in GFAP-positive astrocytes in histone demethylase GASC1/KDM4C/JMJD2C hypomorphic mutant mice.
Mesothelioma
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Mesothelioma, Malignant
Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM).
Mouth Neoplasms
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Multiple Myeloma
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
Lysine Demethylase 5A is Required for MYC Driven Transcription in Multiple Myeloma.
Myocardial Infarction
MiR-134-5p Regulates Myocardial Apoptosis and Angiogenesis by Directly Targeting KDM2A After Myocardial Infarction.
Nasal Polyps
The Role of Epigenetics in the Chronic Sinusitis with Nasal Polyp.
Nasopharyngeal Carcinoma
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
Neoplasm Metastasis
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
KDM4A promotes the growth of non-small cell lung cancer by mediating the expression of Myc via DLX5 through the Wnt/?-catenin signaling pathway.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis.
RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A.
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.
Neoplasms
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
A Lysine (K)-specific demethylase 2B (KDM2B)-let-7-Enhancer of Zester Homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
A molecular threading mechanism underlies Jumonji lysine demethylase KDM2A regulation of methylated H3K36.
A New Family of Jumonji C Domain-Containing KDM Inhibitors Inspired by Natural Product Purpurogallin.
A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 as an Epigenetic Modulator in Prostate Cancer Cells.
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
ALKBH4 promotes tumourigenesis with a poor prognosis in non-small-cell lung cancer.
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
CBP-triggered KDM2B acetylation accelerates the carcinogenesis of colon cancer.
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
Combined expression levels of KDM2A and KDM2B correlate with nucleolar size and prognosis in primary breast carcinomas.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Crystal structures of two inhibitors in complex with histone lysine demethylase 4D (KDM4D) provide new insights for rational drug design.
CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines.
Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.
Discovery of JMJD7 inhibitors with the aid of virtual screening and bioactivity evaluation.
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro.
Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer.
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686.
Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of COBLL1 and the ADAM28-ADAMDEC1 Locus via Interaction with the Histone Lysine Demethylase KDM2B.
Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Expression pattern and regulatory effect of lysine-specific demethylase 2A gene in clear cell renal cell carcinoma.
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
From histones to ribosomes: a chromatin regulator tangoes with translation.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
GASC1 promotes glioma progression by enhancing NOTCH1 signaling.
GASC1 promotes hepatocellular carcinoma progression by inhibiting the degradation of ROCK2.
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project.
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array.
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Heat shock protein 90 (Hsp90) selectively regulates the stability of KDM4B/JMJD2B histone demethylase.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM3A Promotes Cervical Cancer Malignancy Through the ETS1/KIF14/Hedgehog Axis.
Histone demethylase KDM4A plays an oncogenic role in nasopharyngeal carcinoma by promoting cell migration and invasion.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone demethylase KDM4C activates HIF1?/VEGFA signaling through the costimulatory factor STAT3 in NSCLC.
Histone demethylase KDM4C controls tumorigenesis of glioblastoma by epigenetically regulating p53 and c-Myc.
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway.
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines.
Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N4-Erucoyl Spermidine.
Identification of hub genes and key pathways associated with the progression of gynecological cancer.
IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells.
In vitro evidence of NLRP3 inflammasome regulation by histone demethylase LSD2 in renal cancer: a pilot study.
Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion.
Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.
Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
Integrated genomic and functional analyses of histone demethylases identify oncogenic KDM2A isoform in breast cancer.
Interplay between the Epigenetic Enzyme Lysine (K)-Specific Demethylase 2B and Epstein-Barr Virus Infection.
iPSC-Derived Embryoid Bodies as Models of c-Met-Mutated Hereditary Papillary Renal Cell Carcinoma.
JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells.
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
JMJD5 is a potential oncogene for colon carcinogenesis.
JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1?-mediated glucose metabolism.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
KDM2A promotes lung tumorigenesis by epigenetically enhancing ERK1/2 signaling.
KDM2A represses transcription of centromeric satellite repeats and maintains the heterochromatic state.
KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells.
KDM2B in papillomavirus-related cancer.
KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
KDM2B promotes cell viability by enhancing DNA damage response in canine hemangiosarcoma.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4 inhibition targets breast cancer stem-like cells.
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
KDM4A regulates HIF-1 levels through H3K9me3.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma.
KDM4B Overexpression Promotes the Growth, Migration, and Invasion of Rheumatoid Arthritis Fibroblast-Like Synoviocytes by Activating STAT3 Pathway.
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
KDM4B: A Nail for Every Hammer?
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.
KDM5C is transcriptionally regulated by BRD4 and promotes castration-resistance prostate cancer cell proliferation by repressing PTEN.
KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation.
Long non-coding RNA KIKAT/LINC01061 as a novel epigenetic regulator that relocates KDM4A on chromatin and modulates viral reactivation.
LSD1 inhibitors: a patent review (2010-2015).
Lysine demethylase 2A expression in cancer-associated fibroblasts promotes breast tumour growth.
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.
Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Mechanistic insights into KDM4A driven genomic instability.
Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation.
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
Molecular characterization of the porcine JHDM1A gene associated with average daily gain: evaluation its role in skeletal muscle development and growth.
Mutations inhibiting KDM4B drive ALT activation in ATRX-mutated glioblastomas.
Natural variation in the histone demethylase, KDM4C, influences expression levels of specific genes including those that affect cell growth.
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Novel germline variant in the histone demethylase and transcription regulator KDM4C induces a multi-cancer phenotype.
Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.
p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis.
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Possible Role of Lysine Demethylase 2A in the Pathophysiology of Psoriasis.
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Production of ROS by Gallic Acid Activates KDM2A to Reduce rRNA Transcription.
Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing.
RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A.
RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells.
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress.
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy.
TET2 binds the androgen receptor and loss is associated with prostate cancer.
Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The critical role of histone lysine demethylase KDM2B in cancer.
The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
The Lysine Demethylase dKDM2 Is Non-essential for Viability, but Regulates Circadian Rhythms in Drosophila.
The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
The potential underlying mechanism of the leukemia caused by MLL-fusion and potential treatments.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
The Role of KDM2B and EZH2 in Regulating the Stemness in Colorectal Cancer Through the PI3K/AKT Pathway.
The role of the histone demethylase KDM4A in cancer.
Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.
Transcription analysis of a histones modifiers panel coupled with critical tumor suppressor genes displayed frequent changes in patients with AML.: mRNA levels of histones modifiers and TSGs in AML.
Tranylcypromine-Based LSD1 Inhibitors: Structure-Activity Relationships, Antiproliferative Effects in Leukemia, and Gene Target Modulation.
Tudor domain of histone demethylase KDM4B is a reader of H4K20me3.
Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
ZHX2 restricts hepatocellular carcinoma by suppressing stem cell-like traits through KDM2A-mediated H3K36 demethylation.
Neuralgia
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Neuroblastoma
KDM2B regulates choline kinase expression and neuronal differentiation of neuroblastoma cells.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
Neurodegenerative Diseases
LSD1 inhibitors: a patent review (2010-2015).
Neurofibrosarcoma
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Neuroinflammatory Diseases
Histone Demethylase KDM4A Inhibition Represses Neuroinflammation and Improves Functional Recovery in Ischemic Stroke.
Obesity
Correction for Cheng et al., KDM4B protects against obesity and metabolic dysfunction.
JMJD2B/KDM4B inactivation in adipose tissues accelerates obesity and systemic metabolic abnormalities.
Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.
KDM4B facilitates colorectal cancer growth and glucose metabolism by stimulating TRAF6-mediated AKT activation.
KDM4B protects against obesity and metabolic dysfunction.
Osteoarthritis, Knee
Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis.
Osteoporosis
Extracellular Vesicle-Encapsulated miR-29b-3p Released From Bone Marrow-Derived Mesenchymal Stem Cells Underpins Osteogenic Differentiation.
Histone demethylase KDM4A regulates adipogenic and osteogenic differentiation via epigenetic regulation of C/EBP? and canonical Wnt signaling.
Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.
Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging.
The KDM4B-CCAR1-MED1 axis is a critical regulator of osteoclast differentiation and bone homeostasis.
Osteosarcoma
p300 Acetylates JHDM1A to inhibit osteosarcoma carcinogenesis.
Tip60-dependent acetylation of KDM2B promotes osteosarcoma carcinogenesis.
Ovarian Neoplasms
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM4C Is Required for Ovarian Cancer Stem Cell Maintenance.
IL-6 and IL-8 are involved in JMJD2A-regulated malignancy of ovarian cancer cells.
Inhibition of microRNA let-7b expression by KDM2B promotes cancer progression by targeting EZH2 in ovarian cancer.
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
Pancreatic Neoplasms
KDM2B is involved in the epigenetic regulation of TGF-?-induced epithelial-mesenchymal transition in lung and pancreatic cancer cell lines.
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
Pituitary Neoplasms
Synovial Mesenchymal Stem Cell-Derived EV-Packaged miR-31 Downregulates Histone Demethylase KDM2A to Prevent Knee Osteoarthritis.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
KDM2B in polycomb repressive complex 1.1 functions as a tumor suppressor in the initiation of T-cell leukemogenesis.
Prostatic Intraepithelial Neoplasia
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Prostatic Neoplasms
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone Demethylase KDM4C Stimulates the Proliferation of Prostate Cancer Cells via Activation of AKT and c-Myc.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer.
Targeting the KDM4B-AR-c-Myc axis promotes sensitivity to androgen receptor-targeted therapy in advanced prostate cancer.
Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy.
The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
The histone demethylase KDM2B activates FAK and PI3K that control tumor cell motility.
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Upregulated KDM4B promotes prostate cancer cell proliferation by activating autophagy.
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.
Psoriasis
Possible Role of Lysine Demethylase 2A in the Pathophysiology of Psoriasis.
Retinoblastoma
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
Rhabdomyosarcoma
Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A.
Sarcoma, Ewing
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A is not associated with metastasis and prognosis of breast cancer.
Sarcoma, Synovial
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Sepsis
KDM6A Lysine Demethylase Directs Epigenetic Polarity of MDSCs during Murine Sepsis.
Skin Neoplasms
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Small Cell Lung Carcinoma
Electrophilic Zinc Homoenolates: Synthesis of Cyclopropylamines from Cyclopropanols and Amines.
Spinal Cord Injuries
MicroRNA-137-mediated lysine demethylase 4A regulates the recovery of spinal cord injury via the SFRP4-Wnt/?-Catenin axis.
Squamous Cell Carcinoma of Head and Neck
Circular RNA circFOXO3 regulates KDM2A by targeting miR-214 to promote tumor growth and metastasis in oral squamous cell carcinoma.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Starvation
A CxxC Domain That Binds to Unmethylated CpG Is Required for KDM2A to Control rDNA Transcription.
CxxC-ZF Domain Is Needed for KDM2A to Demethylate Histone in rDNA Promoter in Response to Starvation.
JmjC enzyme KDM2A is a regulator of rRNA transcription in response to starvation.
KDM2A-dependent reduction of rRNA transcription on glucose starvation requires HP1 in cells, including triple-negative breast cancer cells.
Mild Glucose Starvation Induces KDM2A-Mediated H3K36me2 Demethylation through AMPK To Reduce rRNA Transcription and Cell Proliferation.
SF-KDM2A binds to ribosomal RNA gene promoter, reduces H4K20me3 level, and elevates ribosomal RNA transcription in breast cancer cells.
Stomach Neoplasms
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
JMJD2A sensitizes gastric cancer to chemotherapy by cooperating with CCDC8.
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis.
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
LINC00460 modulates KDM2A to promote cell proliferation and migration by targeting miR-342-3p in gastric cancer.
Lysine demethylase LSD1 delivered via small extracellular vesicles promotes gastric cancer cell stemness.
MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B.
RUNX3-mediated up-regulation of miR-29b suppresses the proliferation and migration of gastric cancer cells by targeting KDM2A.
Systemic Vasculitis
Correction: Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.
Teratocarcinoma
LSD1 demethylase and the methyl-binding protein PHF20L1 prevent SET7 methyltransferase-dependent proteolysis of the stem-cell protein SOX2.
Tongue Neoplasms
Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model.
Triple Negative Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Urinary Bladder Neoplasms
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Tumor?infiltrating M2 macrophages driven by specific genomic alterations are associated with prognosis in bladder cancer.
Upregulation of JMJD2A promotes migration and invasion in bladder cancer through regulation of SLUG.
Uterine Cervical Neoplasms
Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
HPV16 E7-induced upregulation of KDM2A promotes cervical cancer progression by regulating miR-132-radixin pathway.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Virus Diseases
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
LSD1 inhibitors: a patent review (2010-2015).
[histone h3]-dimethyl-l-lysine36 demethylase deficiency
Genome-wide screens uncover KDM2B as a modifier of protein binding to heparan sulfate.
Kdm2a deficiency in macrophages enhances thermogenesis to protect mice against HFD-induced obesity by enhancing H3K36me2 at the Pparg locus.